Anti-HER2 antibody trastuzumab with chemo is the standard first-line treatment in most ... FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and advanced ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to treatment with Keytruda (pembrolizumab) plus Herceptin (trastuzumab) and fluoropyrimidine- and platinum-containing ...

NCT03615326), which included 698 patients with HER2-positive advanced gastric or GEJ adenocarcinoma not previously treated with systemic therapy for metastatic disease; 85% (n=594) of patients had ...

HER2-positive ... into the HER2 cell. According to recent studies, there is now potential that Enhertu will replace Kadcyla. The treatment of metastatic HER2-positive breast cancer once followed a ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

"Patients in the EU diagnosed with HER2-positive advanced gastric cancer face an aggressive disease associated with a poor prognosis, underscoring the need for additional first-line treatment ...

In particular, the main program of this company is looking at the development of nanobody Lu-RAD204 for the treatment of patients with non-small cell ... HER2 expressing breast and gastric cancer ...

Holist Integ Oncol 1, 4 (2022). [5] Guan, WL.,et al. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol 16, 57 (2023). [6] Jin Li et al., HLX22 plus HLX02 and XELOX for ...

(2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment ...